Quest Diagnostics, Inc (NYSE: DGX) has a higher price-to-earnings ratio of 21.78x compared to its average ratio, The 36-month beta value for DGX is at 0.50. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 1 rating it as “overweight,” 10 as “hold,” and 0 as “sell.”
The public float for DGX is 111.02M, and currently, shorts hold a 3.62% of that float. The average trading volume for DGX on May 21, 2025 was 1.36M shares.
DGX) stock’s latest price update
Quest Diagnostics, Inc (NYSE: DGX) has seen a decline in its stock price by -3.32 in relation to its previous close of 178.24. However, the company has experienced a -0.09% decline in its stock price over the last five trading sessions. zacks.com reported 2025-05-21 that DGX has shown notable strength in the past year, driven by robust core performance and contributions from acquisitions.
DGX’s Market Performance
Quest Diagnostics, Inc (DGX) has experienced a -0.09% fall in stock performance for the past week, with a -0.30% drop in the past month, and a 0.10% rise in the past quarter. The volatility ratio for the week is 1.69%, and the volatility levels for the past 30 days are at 2.07% for DGX. The simple moving average for the past 20 days is -2.29% for DGX’s stock, with a 7.32% simple moving average for the past 200 days.
Analysts’ Opinion of DGX
Many brokerage firms have already submitted their reports for DGX stocks, with Redburn Atlantic repeating the rating for DGX by listing it as a “Buy.” The predicted price for DGX in the upcoming period, according to Redburn Atlantic is $195 based on the research report published on April 02, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see DGX reach a price target of $185. The rating they have provided for DGX stocks is “Neutral” according to the report published on March 04th, 2025.
Leerink Partners gave a rating of “Outperform” to DGX, setting the target price at $174 in the report published on January 06th of the current year.
DGX Trading at 0.86% from the 50-Day Moving Average
After a stumble in the market that brought DGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.26% of loss for the given period.
Volatility was left at 2.07%, however, over the last 30 days, the volatility rate increased by 1.69%, as shares sank -1.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.21% upper at present.
During the last 5 trading sessions, DGX fell by -1.33%, which changed the moving average for the period of 200-days by +13.40% in comparison to the 20-day moving average, which settled at $176.26. In addition, Quest Diagnostics, Inc saw 14.23% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DGX starting from DELANEY MARK E, who sale 874 shares at the price of $175.72 back on May 12 ’25. After this action, DELANEY MARK E now owns 8,372 shares of Quest Diagnostics, Inc, valued at $153,579 using the latest closing price.
DELANEY MARK E, the SVP & Chief Commercial Officer of Quest Diagnostics, Inc, sale 874 shares at $175.31 during a trade that took place back on May 13 ’25, which means that DELANEY MARK E is holding 7,498 shares at $153,221 based on the most recent closing price.
Stock Fundamentals for DGX
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.33 for the gross margin
The net margin for Quest Diagnostics, Inc stands at 0.09. The total capital return value is set at 0.1. Equity return is now at value 13.35, with 6.00 for asset returns.
Based on Quest Diagnostics, Inc (DGX), the company’s capital structure generated 0.49 points at debt to capital in total, while cash flow to debt ratio is standing at 0.23. The debt to equity ratio resting at 0.95. The interest coverage ratio of the stock is 5.65.
Currently, EBITDA for the company is 1.89 billion with net debt to EBITDA at 3.27. When we switch over and look at the enterprise to sales, we see a ratio of 2.52. The receivables turnover for the company is 7.24for trailing twelve months and the total asset turnover is 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.44.
Conclusion
In conclusion, Quest Diagnostics, Inc (DGX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
